THERAPY DOSSIER · th-169d8998ca51

Imatinib

Drug · Tyrosine kinase inhibitor (BCR-ABL, KIT, PDGFR-beta) (INHIBITOR)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Tyrosine kinase inhibitor (BCR-ABL, KIT, PDGFR-beta) (INHIBITOR)
Target: BCR-ABL (CHEMBL2096618); ABL1 (CHEMBL1862); KIT (CHEMBL1936); PDGFRB (CHEMBL1913)
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: 2001
Development stage: Not recorded
ChEMBL record: CHEMBL941 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Imatinib; Gleevec; Glivec; STI-571; CGP-57148B
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00243191 ↗PHASE2completed

Short Course of Neoadjuvant Gleevec (Imatinib) in Dermatofibrosarcoma Protuberans

Dermatofibrosarcoma Protuberans

Enrolment: 18 · Results not recorded

NCT03688568 ↗PHASE2withdrawn

Imatinib in Children With Neurofibromatosis and Airway Tumors

Neurofibroma, Plexiform

Enrolment: 0 · Results not recorded

NCT03862768 ↗NAunknown

Role of Surgery in Focally Progressive GISTs After Imatinib Treatment

Gastrointestinal Stromal Tumors

Enrolment: 92 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25914996 ↗2015Mixed findings

Delayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum Biomarkers.

RatSpinal cord injuryContusionSprague-DawleyFemalen = 90 contusion injured rats plus 10 sham; 4 h delay pilot 5 v…Oral gavage250 mg/kg per day, divided one third in the morning and two…Treatment initiated 4, 8 or 24 h after injury

Model: Thoracic T10 contusion spinal cord injury using an NYU impactor, 10 g weight dropped from 12.5 mm (mild) or 25 mm (moderate)

With a 4 h delay after mild injury, imatinib improved week 10 BBB score (14.2 plus or minus 0.57 versus 12.2 plus or minus 0.24), BBB subscore (3.2 plus or minus 0.37 versus 1.2 plus or minus 0.31), regularity index (81.4 plus or minus 4.7 versus 48.7 plus or minus 6.7 per cent of normal) and bladd…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…